Literature DB >> 16462859

Induction of humoral immunity in response to immunization with recombinant Mycobacterium bovis BCG expressing the S1 subunit of Bordetella pertussis toxin.

Marco A Medeiros1, Geraldo R G Armôa, Odir A Dellagostin, Douglas McIntosh.   

Abstract

Two recombinant Mycobacterium bovis BCG (rBCG) vaccine strains were developed for the expression of cytoplasmically located S1 subunit of pertussis toxin, with expression driven by the hsp60 promoter of M. bovis (rBCG/pPB10) or the pAN promoter of Mycobacterium paratuberculosis (rBCG/pPB12). Both strains showed stable expression of equivalent levels of recombinant S1 in vitro and induced long-term (up to 8 months) humoral immune responses in BALB/c mice, although these responses differed quantitatively and qualitatively. Specifically, rBCG/pPB12 induced markedly higher levels of IgG1 than did rBCG/pPB10, and mice immunized with the former strain developed specific long-term memory to S1, as indicated by the production of high levels of S1-specific IgG in response to a sublethal challenge with pertussis toxin 15 months after initial immunization. When considered in combination with previous studies, our data encourage further evaluation of rBCG as a potential means of developing a low-cost whooping cough vaccine based on defined antigens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16462859     DOI: 10.1139/w05-095

Source DB:  PubMed          Journal:  Can J Microbiol        ISSN: 0008-4166            Impact factor:   2.419


  4 in total

1.  Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG.

Authors:  Susan M Bueno; Pablo A González; Kelly M Cautivo; Jorge E Mora; Eduardo D Leiva; Hugo E Tobar; Glenn J Fennelly; Eliseo A Eugenin; William R Jacobs; Claudia A Riedel; Alexis M Kalergis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

Review 2.  New Insights Contributing to the Development of Effective Vaccines and Therapies to Reduce the Pathology Caused by hRSV.

Authors:  Nicolás M S Gálvez; Jorge A Soto; Alexis M Kalergis
Journal:  Int J Mol Sci       Date:  2017-08-11       Impact factor: 5.923

3.  Recombinant BCG Vaccines Reduce Pneumovirus-Caused Airway Pathology by Inducing Protective Humoral Immunity.

Authors:  Jorge A Soto; Nicolás M S Gálvez; Claudia A Rivera; Christian E Palavecino; Pablo F Céspedes; Emma Rey-Jurado; Susan M Bueno; Alexis M Kalergis
Journal:  Front Immunol       Date:  2018-12-06       Impact factor: 7.561

Review 4.  BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design.

Authors:  Camila Covián; Ayleen Fernández-Fierro; Angello Retamal-Díaz; Fabián E Díaz; Abel E Vasquez; Margarita K Lay; Claudia A Riedel; Pablo A González; Susan M Bueno; Alexis M Kalergis
Journal:  Front Immunol       Date:  2019-11-29       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.